DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3ktbzr/investigation) has announced the addition of the "Chinese Adalimumab Market Report - Forecasts to 2018" report to their offering.
Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA.
It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and developed by BASF Knoll (BASF Pharma) and, ultimately, manufactured and marketed by Abbott Laboratories after the acquisition of BASF Pharma by Abbott. In 2000 Abbott Laboratories took over Knoll with USD 6.9 billion. At the end of 2002 adalimumab was approved to the market by FDA.
Duo to large market size, challenging R&D and high profit of the monoclonal antibody drug market, the collaboration between Huahai Pharmaceutical and Oncobiologics is praised by the industry as the ""Second Transformation"" supported by the international biopharmaceutical giant's strong R&D strength. The approval for adalimumab to launch phase I clinical trial means a significant progress of the collaboration.
However, follow-up R&D of the monoclonal antibody product requires a large amount of time before the product appears on the market. It is estimated that Abbott will continue to occupy the global market of adalimumab in the next few years. However, the situation will change gradually after 2017.
Key Topics Covered:
1 Relevant Concepts of Adalimumab
2 Market Overview of Adalimumab in China, 2010-2013
3 Investigation on Sales Value of Adalimumab in China, 2010-2013
4 Investigation on Market Share of Major Adalimumab Manufacturers in China, 2010-2013
5 Investigation on Market Size of Adalimumab by Dosage Form in China, 2010-2013
6 Reference Price of Adalimumab in China Adalimumab Hospital Market, 2013
7 Analysis on Major Adalimumab Manufacturers in China, 2010-2013
8 Prospect of China Adalimumab Market, 2014-2018
- BASF Bioresearch Corporation
- BASF Pharma
- Huahai Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/3ktbzr/investigation